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Few studies have directly compared the efficiencies of
gene delivery methods that target normal lung cells versus
lung tumor cells. We report the first study directly
comparing the efficiency and toxicity of viral [adeno-
associated virus (AAV2, 5, 6) and lentivirus], nonviral
(Effectene, SuperFect and Lipofectamine 2000) and
physical [particle-mediated gene transfer (PMGT)]
methods of gene delivery in normal mouse lung cells and
in mouse adenocarcinoma cells. Lentivirus pseudotyped
with the vesicular stomatitis virus glycoprotein was the
most efficient gene transfer method for normal mouse
airway epithelial cells [25.95 ( ± 3.57) %] whereas AAV6
was most efficient for MLE-12 adenocarcinoma cells [68.2
( ± 3.2) %]. PMGT was more efficient in normal mouse
airway epithelial cells than AAV5, Lipofectamine 2000 and
SuperFect. AAV5 displayed the lowest transfection
efficiency at less than 10% in both cell types. PMGT was
the only method that resulted in significant toxicity. In
summary, for all of the gene delivery methods examined
here, lung tumor cells were transfected more easily than
normal lung cells. Lipofectamine 2000 is potentially
highly selective for lung tumor cells whereas AAV6 and
lentivirus vesicular stomatitis virus glycoprotein may be
useful for gene delivery strategies that require targeting
of both normal and tumor cells. Anti-Cancer Drugs
19:783–788 c 2008 Wolters Kluwer Health | Lippincott
Williams & Wilkins.
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Introduction
Lung cancer is the leading cause of cancer-related deaths
with 1.2 million cases diagnosed worldwide each year [1].
The increasing ageing population means that the
incidence of lung cancer is likely to increase further.
Despite its prevalence, progress in improving treatment
strategies for lung cancer has been relatively poor.
Advances in conventional chemotherapy, radiation ther-
apy and surgical strategies have had a minimal effect
on survival rates, which remain at less than 15% [1].
Increased understanding of the molecular basis of lung
cancer has stimulated research efforts to develop gene
therapy strategies to treat this disease. However, efforts
to date to deliver genes to lungs have largely focused on
cystic fibrosis as a disease target rather than lung cancer.
As a result, relatively few studies have compared gene
delivery methods to normal versus lung tumor cells.
As with other types of cancer, gene therapy strategies to
treat lung cancer include introduction of tumor suppres-
sor genes and induction of apoptosis, immunogenicity and
drug sensitivity [1]. However, in common with gene
therapy approaches to other diseases, efficient gene
delivery to target tumor cells has proven difficult.
Although several viral vectors such as adenovirus and
adeno-associated virus (AAV) have a natural tropism for
lung epithelial cells, receptors for viral entry are often
downregulated in cancer cells [1]. Immunoreactivity
can also produce serious side effects. Similarly, while
liposome toxicity may be less of an issue for lung cancer
treatment than cystic fibrosis treatment for example, the
efficiency rates of liposomal vectors are still relatively low.
Specific targeting of lung tumor cells also remains a major
challenge for both viral and nonviral approaches.
The respective merits and difficulties associated with
viral and lipid-based/polymer-based gene delivery vectors
have been well documented [2,3]. Gene delivery to the
lungs poses further distinct challenges for gene ther-
apeutics as these organs are well equipped to combat
infection and expel foreign material [3]. Limited success
with viral and lipid-based approaches has led to the
exploration of alternative methods to improve gene
delivery and a variety of physical methods aimed at
improving delivery to lung cells have recently received
new or renewed attention. Particle-mediated gene
transfer (PMGT) uses physical force to deliver material
into cells. PMGT has a number of advantages over
chemical, biological and other physical transfer methods.
This direct transfer method does not rely on expression of
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cell surface receptors, cell division or membrane porosity.
PMGT has primarily been used with cells that are
difficult to transfect and it has also been used to transfect
tissues such as liver in vivo [4].
Most gene therapy strategies to treat lung cancer will
need to maximize delivery to tumour cells while
minimizing targeting of their normal counterparts. Some
strategies, however, may require delivery to normal cells
also. Progress in identifying lung stem cells and lung
cancer stem cells has been made in recent years. It has
been proposed that both normal airway and alveolar
epithelial cells and adenocarcinomas arise from the same
population of cells in distal mouse airways, termed as
bronchioalveolar stem cells [5]. To assess the ability of
different delivery methods to specifically transfect lung
tumour cells, we carried out an extensive evaluation of
the relative efficiencies and toxicities of viral, nonviral
and physical modes of gene delivery in normal mouse
airway cell cultures and in MLE-12 cells, which are
derived from mouse lung adenocarcinomas.
Few studies have been carried out to date in any cell type
to directly compare the transfection efficiencies of viral,
liposome and physical methods of gene delivery. Further-
more, compared with adenovirus, the ability of AAV
vectors to transfect lung cells has not been widely
examined [1]. A study of AAV1, 2, 4, 5, 6, lentivirus
pseudotyped with the vesicular stomatitis virus glycopro-
tein (HIV-VSV-G) and Lipofectin (Invitrogen, Paisley,
UK) vectors in rat mesenchymal stem cells found that
HIV-VSV-G was most efficient in these cells [6]. Another
study using rat cardiomyocytes compared AAV2, electro-
poration and a range of polysomal and liposomal methods
of gene delivery [7]. Lipofectamine 2000 and AAV2 were
the most efficient nonviral and viral methods of delivery,
respectively, whereas electroporation was more efficient
than liposomes [8]. To our knowledge, no such study has
been carried out comparing normal and transformed cells
using a wide range of delivery methods or that uses any
type of lung cells.
Materials and methods
Cell culture
Normal primary mouse lung cells were freshly isolated
from female C3H-Hen mice as described previously [9].
These mouse airway epithelial cell (MAEC) cultures
comprise approximately 80% Clara cells and 20% ciliated
cells. MAECs are isolated in clumps and therefore cell
counting using a hemocytometer is not feasible. To
ensure equal seeding densities, an aliquot of cell isolate
was taken before seeding and an absorbance value (A450)
was obtained using the Cell Titer 96 AQueous One
Solution Cell Proliferation Assay (Promega Corp, Madi-
son, Wisconsin, USA). Cell suspensions were diluted
appropriately based on A450 values to obtain equal
seeding densities. MLE-12 cells were obtained from
ATCC (Manassas, Virginia, USA). Cells were seeded in
culture medium [1:1 Hams F12:M199 (Gibco, Glasgow,
UK), 10% fetal bovine serum, 2mmol/l L-glutamine
(Gibco), 100U/ml penicillin and 100 mg/ml streptomycin
(Gibco)].
Adeno-associated virus transfections
AAV vector production was carried out as described
previously [6]. Cells were plated at a concentration of
3.5 103 cells/well in 24-well tissue culture plates
(Sarstedt, Wexford, Ireland). Following 48 h attachment,
supernatants were removed and cells were rinsed once
in OptiMEM (Gibco). OptiMEM (400 ml) containing
5107, 5108 or 5109 plaque-forming units of AAV2-
green fluorescent protein (GFP), AAV5-GFP or AAV6-
GFP was added and cells were incubated for 5 h at 371C,
5% CO2 and 95% air. Supernatants were removed and
fresh culture medium was added. After 24 or 48 h, cells
were harvested by trypsinization and resuspended in
phosphate-buffered saline containing 1% formaldehyde.
GFP expression was quantified using a FACScan Flow
Cytometer (Becton Dickinson, Oxford, UK).
Lentiviral transfections
Third generation rHIV-1-based lentivirus pseudotyped
with VSV-G envelope and expressing GFP under the
control of phosphoglycerate kinase promoter was pre-
pared as described previously [6]. Cells were seeded at
3.5 103 cells/well in a 24-well plate and transduced
48 h later. Cells were transduced with 7.5104, 1.5105
or 2.25105 plaque-forming units in 400 ml OptiMEM.
GFP analysis was performed as described above for
AAV-GFP.
Lipid transfections
Cells were seeded at 1.92104 cells/well and transfected
48 h later. Lipofectamine 2000 (Invitrogen) was com-
plexed to pMGFP (Promega) in a ratio of 0.4 mg: 0.75 mg
(lipid: DNA). pMGFP was incubated in 100 ml OptiMEM
at room temperature, lipid was added and the lipoplex
was allowed to form by incubating for 30min at room
temperature. The lipoplex solution was added to each
well and OptiMEM was added to a final volume of 200 ml.
For Effectene transfections, for each well, a solution
containing 0.66 mg pMGFP, 100 ml Buffer EC (Qiagen,
Sussex, UK) and 1.28 ml of Enhancer (Qiagen) was
incubated for 5min at room temperature. Effectene
(1.6 mg) (Qiagen) was added and incubated for a further
30min. The volume was increased to 200 ml with
OptiMEM and added to cells. For SuperFect transfec-
tions, for each well, 0.578 mg pMGFP in 100 ml OptiMEM
was incubated at room temperature for 5min. SuperFect
(4 ml) was added and incubated for a further 30min.
OptiMEM was added to a final volume of 200 ml and
added to cells. For all lipid transfections, cells were
incubated for 6 h at 371C, 5% CO2 and 95% air after
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which 200 ml culture medium was added. At 24 and 48 h,
cells were harvested and GFP analysis was performed as
described above for AAV-GFP.
Gene gun bombardment
MAECs were seeded into 35-mm2 tissue culture dishes
(NalgeNunc, New York, USA). Cells required for
subsequent analysis by fluorescence microscopy were
grown on glass cover slips placed in the culture dishes.
Cells were seeded at a density of 0.1 absorbance unit per
dish as determined by the Cell Titer 96 AQueous One
Solution Cell Proliferation Assay described above.
Bombardment was carried out 24 h later. pMGFP was
precipitated onto gold microcarriers as follows: briefly,
50 ml pMGFP (1 mg/ml), 50 ml 2.5mol/l CaCl2, 20 ml 0.1
mol/l spermidine and 3mg 1.6 mm gold particles (BioRad,
California, USA.) were mixed then rinsed once with 70%
EtOH, once with 100% EtOH and resuspended in 60 ml
100% EtOH. Aliquots (6 ml) were spread onto macro-
carriers (BioRad). Cells were bombarded with a Biolistic
PDS-1000/He gun (BioRad) using 900 psi rupture discs
and a vacuum of 15 in Hg. The macrocarrier and stopping
screen assembly was placed on the top shelf and the
tissue culture dish was also placed on the top shelf
such that distances from the tissue culture dish to the
stopping screen and from the stopping screen to the
rupture disc were approximately 3.0 and 2.5 cm, respec-
tively.
Cell viability
For viability assessment of cells following viral and
nonviral methods of transfection, cells were harvested
by trypsinization at each time point and viability counts
were carried out using ethidium bromide/acridine orange
staining with an ultraviolet microscope. For viability
assessment following gene gun bombardment, cells were
analyzed by flow cytometry. Viable cells were gated as
determined by cell size and granularity. Cells outside of
this population were deemed nonviable.
Results and discussion
We compared the transfection efficiencies and toxicities
of a range of the most commonly used viral vectors
(AAV2, AAV5, AAV6 and HIV-VSV-G), commercial non-
viral vectors [Effectene (Qiagen), SuperFect (Qiagen)
and Lipofectamine 2000 (Invitrogen)] and the physical
method of gene gun bombardment using GFP reporter
transgenes. Preliminary experiments were carried out
using wide ranges of concentrations of each viral and
nonviral vector to determine narrower ranges of optimal
transfection efficiencies, and to minimize toxicity in the
case of the nonviral vectors (data not shown). Optimal
parameters for gene gun bombardment were also
determined before this study (data not shown). For viral
and nonviral methods, GFP expression was determined
at 24 and 48 h time points post-gene delivery so that
toxicity, differences in vector expression time, and
variations in cell cycle rates between the cell types could
be taken into account. Because cell damage was high
using the PMGT method, GFP expression was measured
at 24 h only for this method.
Viral and nonviral delivery at 24 h. An increase in GFP
expression was observed with increasing titers of all viral
vectors in both cell types at both 24 and 48 h time points
except for HIV-VSV-G in MAECs at 24 h. The highest
level of transgene expression in primary MAECs at 24 h
post transfection was achieved with AAV6, which
transfected 23 (±7.29) % of cells (Fig. 1a). HIV-VSV-G
ranked second best in MAECs with an efficiency of 10.8
(±1.59) % followed by Effectene, which was the most
efficient nonviral vector at 7 (±1.9) %.
AAV6 was also the most efficient vector in MLE-12 cells
at 68.2 (±3.2) %. Lipofectamine 2000 was next best and
was the most efficient nonviral vector at 55.89 (±4.07)
%. AAV5 performed poorly in both cell types with GFP
detected in less than 10% of cells.
Cell viability was determined in each cell line after
transfection with each vector. No significant toxic effect
was observed with any of these delivery methods at 24 h
(data not shown).
Viral and nonviral delivery at 48 h. At 48 h, the percentage of
GFP-positive MAECs transfected using AAV6 had de-
creased to 14.44 (±10.93) % (Fig. 1b). In contrast, the
percentage of GFP-positive MAECs transfected using
HIV-VSV-G had increased from 10.79 (±1.58) % at day 1
to 25.95 (± 3.57) % at day 2. This was the highest
transfection rate achieved in MAECs at either time point
with any method.
In MLE-12 cells, the level of AAV6-GFP expression was
also reduced from 24 h to 56.02 (±4.39) %. A slight
increase in GFP expression from 24 h with Lipofectamine
2000 transfection was observed in MLE-12 cells with a
transfection efficiency of 61.49 (±5.05) %.
No significant toxic effect was observed with any of these
delivery methods at this time point (data not shown).
Particle-mediated gene transfer. Bombardment was carried
out in 35-mm2 tissue culture dishes. Cells were
approximately 90% confluent. The target area of the
gene gun was calculated to be approximately 20% of the
surface area of the dish. Therefore, 20% of the total cell
population was targeted. Whereas MLE-12 cells were
bombarded once per experiment, MAECs were bom-
barded twice because primary cells are more difficult to
transfect by this method and no transgene expression
was detected after a single bombardment (data not
Comparison of gene delivery methods to lung cells Gilbert et al. 785
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Transfection efficiencies of viral, nonviral and physical gene delivery methods in mouse airway epithelial cells (MAECs) and MLE-12 cells. (a) 24h post-
transfection. AAV6 was the most efficient vector in both cell types at this time point although at the highest titer of AAV, the green fluorescent protein
(GFP) reporter was expressed in three times as many MLE-12 cells as MAECs. The greatest difference in transfection efficiency between cell types
occurred with Lipofectamine, which transfected 10 times more MLE-12 cells than MAECs. (b) 48 h post-transfection. Compared with the 24h time
point, a reduction in GFP expression was evident with all vectors except HIV-VSV-G and Lipofectamine 2000 at 48 h with the latter producing both the
highest overall rate of transfection in MLE-12 cells and the greatest difference in transfection efficiency between the cell types. Student’s t-test was
used to determine significance, *P<0.05; **P<0.01; ***P<0.001. (c) Gene gun bombardment of MAECs and MLE-12 cells. GFP fluorescence
was observed in both cell types 24h post-transfection, arrows indicate gold particles. (d) GFP expression was detected in approximately 25 and 35%
of targeted MAECs and MLE-12 cells, respectively, with the gene gun bombardment method. AAV, adeno-associated virus.
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shown). 24 h after bombardment, cells were analyzed
by fluorescence microscopy and flow cytometry for GFP
expression.
The targeted area was identifiable using a microscope
due to the presence of gold particles (Fig. 1c). Within this
area, GFP expression was observed in both cell types.
Total cell populations were harvested from culture dishes
by trypsinization and analyzed by flow cytometry. GFP
expression in the total MAEC and MLE-12 populations
was 5.04 (±3.6) % and 7.11 (±3.2) %, respectively.
However, because only 20% of the total population had
been targeted, these figures can be adjusted 25.2 (±18)
% and 35.55 (±16) %, respectively (Fig. 1d). This means
that PMGT was almost as efficient as HIV-VSV-G,
although more toxic than the viral method. Because
MAECs were bombarded twice, the procedure was
relatively harsh on these cells with only 58.98 (±9.15)
% of cells remaining viable 24 h post bombardment. The
treatment was less damaging to MLE-12 cells, which
were only bombarded once, with 86.13 (±4.17) % of
cells remaining viable at 24 h (data not shown).
Primary MAECs, MLE-12 cells, AAV6 vectors and HIV-
VSV-G all have been used in only a small number of lung
gene delivery studies to date. As expected, primary
MAECs were generally more difficult to transfect than
transformed MLE-12 cells. Negligible levels of transfec-
tion were achieved in MAECs using AAV5, Lipofectamine
2000 and SuperFect, with the nonviral vectors performing
particularly poorly. With Effectene, GFP expression was
detected in approximately 10% of cells at 48 h. The
highest levels of transfection in MAECs were achieved
with AAV6 at 24 h and HIV-VSV-G at 48 h with efficiency
levels approaching 30% and no significant toxicity.
Compared with primary MAECs, MLE-12 cells were
markedly easier to transfect with AAV6, HIV-VSV-G and,
most strikingly, Lipofectamine 2000. AAV6 performed the
best in these cells. These data indicate that AAV6 or HIV-
VSV-G may serve as suitable vectors to target both normal
and tumour cells, whereas Lipofectamine 2000 may be
useful to achieve selective targeting of tumour cells over
normal cells.
Previous studies report that AAV5 and AAV6 transfect
lung cells more efficiently than AAV2 [10,11]. However,
in this study, relative efficiencies of the AAV vectors
in MLE-12 cells were AAV6> >AAV2> >AAV5. AAV5
performed particularly poorly with efficiencies of less
than 10% in each cell type. Studies with AAV5 and AAV6
in lung cells to date have been limited. Our results may
represent differences in cell types or model systems
compared with previous studies and may suggest that the
transduction capability of AAV5 is more limited than
previous studies indicate. Lipofectamine 2000 achieved
high gene transfer efficiencies in MLE-12 cells but not in
MAECs. This may reflect differences in cell cycle rates as
cell division within the primary cell cultures is slower
than that of the cell lines and lipofection requires
breakdown of the nuclear membrane for entry to the
nucleus.
High transfection efficiencies can be offset by high
toxicity with some vectors. This was not the case in this
study, however, as no significant reduction in cell viability
occurred with the best performing viral and nonviral
vectors. Notably, AAV2 appeared to have a growth-
promoting effect on MLE-12 cells by 48 h, which may
also be undesirable, however, in the context of antitumor
therapy.
The physical gene delivery method of gene gun bombard-
ment was also evaluated. With the system used in this
study, the target cells are bombarded under vacuum using
a high-pressure helium burst to launch the particles at the
target cells. The experimental procedure is relatively
harsh on the cells and parameters require optimization to
minimize cell damage. Cells exposed to vacuum for
prolonged periods become stressed and may die. The
helium blast used to transfer the particles also has a blast
effect on the cells. The spread of particles before impact
must also be accounted for. When the microparticles are
launched at the target site, they have to cover a distance
of at least 3 cm before impact with the cells making it
difficult to specifically target areas on the culture dish and
only a proportion of the dish can be targeted.
Despite these difficulties, both cell types were success-
fully transfected using the gene gun in this study.
Accurate evaluation of transfection efficiency and direct
comparison with the viral and nonviral methods was not
possible, however, because only a subpopulation of the
total population harvested from the dishes for analysis
after bombardment was actually targeted. However, the
viral and nonviral methods are likely to be more efficient
methods of transfecting MLE-12 cells. Although cell
damage was minimal with MLE-12 cells, the procedure
was lethal in about 50% of MAECs. Further optimization
of experimental parameters may reduce the extent of cell
damage. Nonetheless, within the area targeted, approxi-
mately 25% of MAECs were transfected. It can therefore
be concluded that bombardment is a more efficient gene
delivery method for primary mouse cells than AAV5,
Lipofectamine 2000 and SuperFect. If bombardment was
combined with a method for selecting transfected cells,
such as fluorescence-activated cell sorting, this would
provide the means of transfecting primary lung cells
in vitro without the disadvantages associated with viral
and nonviral vectors.
In conclusion, all gene delivery methods examined here
indicate that lung tumour cells are transfected more
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easily than normal lung cells. AAV6 and VSV-G may be
useful for gene therapy strategies that require targeting of
both normal and tumour cells whereas Lipofectamine
2000 is potentially highly selective for lung tumour cells.
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